---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-070337"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T19:44:41.450440+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics Q1 2025 net loss narrows to $4.1M; cash runway into Q1 2027

## Summary
- Net loss attributable of $4.1M ($0.02/shr) vs $6.5M ($0.04/shr) in Q1 2024; revenue $1.5M (flat YoY).
- Cash and marketable securities of $47.9M as of Mar 31, 2025 expected to fund operations into Q1 2027.
- OpRegen 36-month data to be presented June 21 at CTS 2025; OPC1 DOSED study initiated Feb 2025 for spinal cord injury.
- 3rd Annual SCI Investor Symposium announced with Christopher & Dana Reeve Foundation, virtual starting June 27, 2025.

## SEC filing metadata
- accession: 0000950170-25-070337
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000095017025070337/0000950170-25-070337-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000095017025070337/lctx-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-070337
- JSON: https://secwatch.observer/filing/0000950170-25-070337.json
- Plain text: https://secwatch.observer/filing/0000950170-25-070337.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.